NCT00974272View on ClinicalTrials.gov

Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation

PHASE4CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Type 2 Diabetes MellitusImpaired Glucose Tolerance
Interventions
DRUG

Exenatide

Single subcutaneous injection (10 μg)

OTHER

Normal Saline

Single subcutaneous injection

Trial Locations (1)

85012

Phoenix VA Medical Center, Phoenix

All Listed Sponsors
lead

Carl T. Hayden VA Medical Center

FED

NCT00974272 - Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation | Biotech Hunter | Biotech Hunter